10Mês·

Da läuft einiges bei $CHRS (-0,71%)

----

Big news! Our parent company, Intas Pharmaceuticals, Ltd. has signed an agreement to acquire the UDENYCA® (pegfilgrastim-cbqv) business from 

@Coherus_Bio

. We look forward to next steps as we work to expand our portfolio of patient-centered therapies across our therapeutic areas of focus. Learn more: http://prn.to/3B8FybY

2
4 Comentários

imagem de perfil
Hintergrundinfo?
imagem de perfil
Are you buying again?
imagem de perfil
@Max095 currently not
imagem de perfil
@swissky only bought more yesterday at $BLUE, fortunately before the 🚀
1
Participar na conversa